Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines

초록

This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelinesfor the management of cer vical cancer incorporates recent research findings and changes intreatment strategies based on version 4.0 released in 2020. Each key question was developedby focusing on recent notable insights and crucial contemporar y issues in the field of cer vicalcancer. These questions were evaluated for their significance and impact on the currenttreatment and were finalized through voting by the development committee. The selected keyquestions were as follows: the efficacy and safety of immune checkpoint inhibitors as first-or second-line treatment for recurrent or metastatic cer vical cancer; the oncologic safety ofminimally invasive radical hysterectomy in early stage cer vical cancer; the efficacy and safetyof adjuvant systemic treatment after concurrent chemoradiotherapy in locally advancedcer vical cancer; and the oncologic safety of sentinel lymph node mapping compared topelvic lymph node dissection. The recommendations, directions, and strengths of thisguideline were based on systematic reviews and meta-analyses, and were finally confirmedthrough public hearings and external reviews. In this study, we describe the revised practiceguidelines for the management of cer vical cancer.

키워드